From financials, abbvie not only has revenues but also profits, which is a demonstration of value generation and therefore a good fit for long-only investment. Abbvie's EPS has been growing steadily over the years and its most recent EPS growth rate reaches 21% over the three years. Abbvie's EBIT margins are steadily maintained over the last year as well. From activities, Abbvie very recently buys Belgian drug company Syndesi Therapeutics for about $130 million to give it ownership of the firm in neuroscience field like cognitive decline and depression. Building upon company's expertise in immunology, the firm will now have more development in neuroscience field as well, which represents potentials in growth from such diversification.